From Concept to
Conjugate-Ready
ADC
Bring us your antibody and your linker-payload — we handle the conjugation, characterization, and formulation. From first conjugate to in vivo-ready material, iQ Biosciences supports every stage of your ADC program.
- Conjugate linker-payloads to your antibodies — ADC, DAC, AOC, fluorescent dyes & more
- Multiple conjugation methods — stochastic and site-specific
- High-throughput (HTP) conjugation — many antibodies × many payloads, in parallel
- µg to 1–2 g scale — from proof-of-concept to in vivo ready
- Full analytical characterization — DAR, purity, LC-MS, bioassays
- Formulation & stability — buffer screening, freeze-thaw, scale-up
Where Are You in Your ADC Development?
Jump directly to the stage that matches where you are — or let us support you across all three. You provide the antibody and linker-payload; we take it from there.
- ADC, DAC, AOC & more
- Stochastic & site-specific methods
- BsAb, IgG1, dual payload, scFv
- High-throughput screening
- Small scale → 1–2g in vivo scale
- DAR by LC-MS & HIC
- Purity by RP-HPLC & SEC
- Structural characterization (Q-TOF)
- Plasma stability & lysosomal release
- In vitro bioassays
- Buffer screening & optimization
- Freeze-thaw stability studies
- Lot-to-lot consistency at scale
- FPLC purification & scale-up
- Pre-IND process development
Stage 1 — Conjugate Them
We Conjugate Your Linker-Payload to Your Antibody
Bring us your antibody and your linker-payload — we handle the conjugation chemistry. From exploratory small-scale batches to in vivo-ready gram-scale production, we deliver high-quality conjugates with full flexibility on format and method.
Antibody-Drug Conjugates (ADC)
The gold standard in targeted oncology. You provide the antibody and linker-payload; we conjugate them using the chemistry best suited to your combination and goals.
Degrader-Antibody Conjugates (DAC)
Conjugating antibodies to PROTAC or molecular glue payloads for next-generation targeted degradation. You supply the antibody and degrader payload; we handle the conjugation.
Antibody-Oligonucleotide Conjugates (AOC)
Conjugating antibodies to oligonucleotide payloads (siRNA, ASO, mRNA) for targeted gene silencing. You provide the antibody and oligonucleotide; we perform the conjugation.
Stochastic Conjugation
- Native cysteine conjugation
- Native lysine conjugation
- Broad DAR distribution, cost-effective
- Ideal for early-stage screening
Site-Specific Conjugation
- Engineered cysteine (THIOMAB)
- Glycan conjugation
- ‘Click’ chemistry (DBCO/azide)
- Unnatural amino acid incorporation
Research & Tool Conjugates
Beyond therapeutic conjugates, we support antibody labeling for research, assay development, and detection workflows.
- Antibody–fluorophore conjugates for flow cytometry and imaging
- Enzyme conjugates (HRP, alkaline phosphatase)
- Biotinylated antibodies and detection reagents
- Custom antibody labeling for assay development
From Proof-of-Concept to In Vivo Ready
We scale conjugation to match your study needs — from microgram-level screening batches to gram-scale production sufficient for in vivo efficacy and PK/PD studies. The same antibody and linker-payload you provide at small scale is conjugated with the same consistency at every scale.
Stage 2 — Characterize Them
Know Exactly What You Made
Rigorous characterization is the bridge between conjugation and confidence. We provide the analytical data you need to understand your conjugate’s purity, drug loading, structural integrity, and biological behavior.
Drug-Antibody Ratio (DAR)
Precise DAR determination by HIC and LC-MS. We report average DAR, DAR distribution, and species profiling to confirm your conjugation efficiency.
Purity Analysis
RP-HPLC and SEC-HPLC to assess aggregation, monomer content, and unconjugated antibody or free drug levels. Know your product is clean before moving forward.
Structural Characterization (LC-MS)
Q-TOF LC-MS provides intact and reduced mass analysis and peptide mapping to confirm conjugation site, payload attachment, and molecular integrity of your ADC.
Plasma Stability Assay
Evaluate linker stability in relevant species over time. Critical for understanding conjugate integrity and deconjugation kinetics, supporting informed decisions prior to in vivo studies.
Lysosomal Release Assay
Confirm that your payload is released in the lysosomal compartment as intended — a key mechanistic readout for cleavable linker ADCs.
Target Binding & Internalization
Verify that conjugation has not compromised antigen binding affinity and confirm receptor-mediated internalization kinetics in relevant cell lines. Optional Kupffer cell uptake assays can be included to assess off-target internalization and inform PK risk.
State-of-the-Art Analytical Instrumentation
Our analytical platform is built around industry-standard instruments used in ADC development programs at major pharma and biotech companies. All data is delivered in report-ready format.
In Vitro Validation Assays
Functional characterization to confirm your ADC performs as intended in cell-based models.
Stage 3 — Formulate & Scale
Store It Right. Scale It Consistently.
A great conjugate is only as good as its formulation. We help you identify the right buffer conditions, confirm stability across freeze-thaw cycles, and reproduce your conjugate at larger scale with the same quality you saw at the bench.
Buffer Screening & Optimization
We systematically test your ADC across a panel of buffer conditions to identify the formulation that best preserves stability, activity, and physical integrity.
- pH range screening
- Excipient panel (sugars, surfactants, salts)
- Accelerated stability testing
- Aggregation monitoring by SEC
Freeze-Thaw Stability Studies
Understand how your ADC behaves through multiple freeze-thaw cycles — critical for storage, shipping, and dosing protocols in in vivo studies.
- Multiple freeze-thaw cycle testing
- Time-point sampling (T=0, 1wk, 1mo, 3mo)
- Analytical readouts at each time point
- Long-term storage condition recommendations
Scale-Up with Lot-to-Lot Consistency
Reproduce your optimized conjugate at larger scale without sacrificing quality. We apply the same process parameters to ensure your in vivo material matches your discovery-stage benchmarks.
- Process transfer from small to large scale
- FPLC-based purification at scale
- Ultracentrifugation for aggregate removal
- Full QC panel on each lot
Reproducibility You Can Count On
When you move from a 1 mg discovery batch to a 1–2 g in vivo lot, the last thing you want is a different product. Our process development team ensures that every scale-up is a faithful reproduction — same DAR, same purity, same activity.
Built for ADC Discovery Programs
Fastest Turnaround in the Industry
Streamlined workflows and dedicated conjugation scientists mean your project moves without unnecessary delays.
Conjugation Through Formulation, Under One Roof
Conjugate, characterize, and formulate your ADC with a single CRO partner — no handoffs, no gaps, no surprises. You provide the components; we deliver the finished conjugate.
Scale When You’re Ready
From a few micrograms for screening to 1–2 g for in vivo studies — we scale with your program, not against it.
Analytical Rigor at Every Step
Q-TOF LC-MS, UHPLC, HIC, and a full bioassay suite ensure you always know exactly what you have.
Transparent, Collaborative Partnership
Regular updates, detailed reports, and direct access to our scientists — not just a data dump at the end.
Competitive Pricing, Free Consulting
Every quote includes a complimentary consultation to make sure you’re ordering exactly what your program needs.
Ready to Start Your Bioconjugation Project?
Tell us where you are in your journey and we’ll build a plan around your timeline and budget. Quotes are free — and so is the expert advice that comes with them.
